Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: A randomised multicentre study of active disease using MRI and clinical criteria

Journal of Neurology Neurosurgery and Psychiatry

Volumn 62, Issue 2, 1997, Pages 112-118

  Edan, Gilles ^a,h   Miller, David ^b   Clanet, Michel ^c   Confavreux, Christian ^d   Lyon Caen, Olivier ^e   Lubetzki, Catherine ^e   Brochet, Bruno ^f   Berry, Isabelle ^c   Rolland, Yan ^a   Froment, Jean Claude ^d   Dousset, Vincent ^f   Cabanis, Emmanuelle ^e   Iba Zizen, Marie Thérèse ^e   Gandon, Jean Marc ^g   Lai, H M ^b   Moseley, Ivan ^b   Sabouraud, Olivier ^a  

^a RENNES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c CHU PURPAN   (France)

^d Hopital de l'Antiquaille   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f BORDEAUX UNIVERSITY HOSPITAL   (France)

^g Biotrial   (France)

^h PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Magnetic resonance imaging; Methylprednisolone; Mitoxantrone; Multiple sclerosis

Indexed keywords

ANTINEOPLASTIC AGENT; GADOLINIUM PENTETATE; METHYLPREDNISOLONE; MITOXANTRONE; STEROID;

ADULT; ALOPECIA; AMENORRHEA; ANEMIA; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; DRUG EFFICACY; FEMALE; FRANCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT; SKIN DISEASE; TACHYCARDIA; URINARY TRACT INFECTION; VOMITING;

EID: 0031040238     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.62.2.112     Document Type: Article

References (33)

1. British and Dutch Multiple Sclerosis Azathioprine Trial Group. Double-masked trial of azathioprine in multiple sclerosis. Lancet 1988;ii:179-83.
2. Goodkin DE, Bailly RC, Teetzen ML, Hertsgaard D, Beatty WW. The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology 1991;41:20-5.
3. Kappos L, Patzold U, Dommash D, Poser S, Haas J, Krauseneck P, et al. Cyclosporine versus aziathioprine in long-term treatment of multiple sclerosis - Results of the German multicenter study. Ann Neurol 1988;23:56-63.
4. The multiple Sclerosis Study Group. The efficacy and toxicity of cyclosporine A in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. Ann Neurol 1990;27:591-605.
5. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The cooperative multiple sclerosis study group. Lancet 1991;337:441-6.
6. Weiner HL, Mackin GA, Orav EJ, Hafler DA, Dawson DM, Lapierre Y, et al and the Northeast Cooperative Multiple Sclerosis Treatment Group. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis. Neurology 1993;43:910-8.
7. Goodkin DE, Rudick RA, Medendorp SV, Daughtry MM, Scwetz KM, Fischer J, Van Dyke C. Low dose oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995;37: 30-40.
8. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43: 655-61.
9. Paty DW, Li DKB; the UBC MS/MRI Study Group; and the IFNB Multiple Sclerosis Study. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-7.
10. Jacobs LD and the Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-94.
11. Rosenberg LS, Carvlin MJ, Krugh TR. The antitumor agent mitoxantrone binds cooperatively to DNA: evidence for heterogeneity in DNA conformation. Biochemistry 1986;25:1002-8.
12. Fidler JM, Dejoy SQ, Gibbons JJ. Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. J Immunol 1986;137:727-32.
13. Fidler JM, Dejoy SQ, Smith FR, Gibbons JJ. Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Non specific adherent suppressor cells derived from mitoxantrone-treated mice. J Immunol 1986;136:2747-54.
14. Ridge SC, Sloboda AE, Reynolds RA, Levine S, Oronsky AL, Kerwar SS. Suppression of experimental allergic encephalomyelitis by mitoxantrone. Clin Immunol Immunopathol 1985;35:35-42.
15. Levine S, Saltzman A. Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone. J Neuroimmunol 1986;13:175-81.
16. Lublin FD, Lavasa M, Viti C, Knobler RL Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. Clin Immunol Immunopathol 1987;45:122-8.
17. Gonsette RE, Demonty L. Immunosuppression with mitoxantrone in multiple sclerosis: a pilot study for 2 years in 22 patients [abstract]. Neurology 1990;40(suppl 1):261.
18. Kappos L, Gold R, Künstler E, Rohrbach E, Reinhard H, Detlef S, Hofmann E. Mitoxantrone in the treatment of rapidly progressive multiple sclerosis: a pilot study with serial gadolinium-enhanced MRI [abstract]. Neurology 1990;40(suppl 1):261.
19. Mauch E, Kornhuber MH, Krapf H, Fetzer U, Laufen H. Treatment of multiple sclerosis with mitoxantrone. European Archives of Psychiatry and clinical Neuroscience. 1992;242:96-102.
20. Noseworthy JH, Hopkins MB, Vandervoot MK, Karlik SJ, Lee DH, Penman M, et al. An open-trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology 1993;43:1401-6.
21. Bastianello S, Pozzilli C, D'Andrea F, Millefiorini E, Trojano M, Morino S, et al. A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. Can J Neurol Sci 1994;21:266-70.
22. De Castro S, Domenico C, Millefiorini E, Funaro S, Gasperini C, Morino S, et al. Noninvasive assessment of mitoxantrone cardiotoxicity in relapsing remitting multiple sclerosis. J Clin Pharmacol 1995;35:627-32.
23. Confavreux C, Compston DAS, Hommes OR, McDonald WI, Thompson AJ. Edmus, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry 1992; 55:671-6.
24. Miller DH, Barkhof F, Berry I, Kappos L, Scotti S, Thompson AJ. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry 1991;54: 683-8.
25. Miller DH, Albert PS, Barkoff F, Francis G, Frank JA, Hodgkinson S, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 1996;39:6-16.
26. McFarland HF, Frank JA, Albert PS, Smith ME, Martin R, Harris JO, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992;32:758-66.
27. Stone LA, Frank JA, Albert PS, Bash C, Smith ME, Maloni H, McFarland HF. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995;37:611-9.
28. Moreau T, Thorpe J, Miller DH, Moseley IF, Hale G, Waldmann H, et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 1994; 344:298-301.
29. Miller DH, Barkhof F, Nauta JJP. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 1993;116:1077-94.
30. Miller DH, Thompson AJ, Morissey SP, MacManus DG, Moore SG, Kendall BE. High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry 1992;55:450-3.
31. Crossley RJ. Clinical safety and tolerance of mitoxantrone. Sem Oncol 1984;11(suppl. 1):54-9.
32. Posner LE, Dukart G, Goldberg J, Bernstein T, Cartwright K. Mitoxantrone: an overview of safety and toxicity. Investigational New Drugs 1985;3:123-32.
33. Stone LA, Smith ME, Albert PS, Bash CN, Maloni H, Frank JA, McFarland HF. Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis. Neurology 1995;45: 1122-6.